Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Core Viewpoint - Alpha Tau Medical Ltd. has successfully treated the first patient in the world with its Alpha DaRT technology for recurrent glioblastoma multiforme (GBM), marking a significant milestone in cancer treatment [3][4]. Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of Alpha DaRT for solid tumors [9]. - The Alpha DaRT technology was initially developed by professors from Tel Aviv University [9]. Technology Details - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) utilizes intratumoral delivery of radium-224 sources to emit high-energy alpha particles, aiming to destroy tumors while sparing surrounding healthy tissue [10]. - The technology is designed to provide highly potent and conformal alpha-irradiation specifically targeting solid tumors [10]. Clinical Study Insights - The pilot study aims to enroll up to ten U.S. patients with recurrent glioblastoma who are not suitable for surgical resection and have previously undergone central nervous system radiation [8]. - The primary objective of the study is to evaluate the feasibility and safety of the Alpha DaRT treatment, following promising preclinical results [8]. Treatment Significance - The treatment of GBM patients with Alpha DaRT addresses a critical need for new local therapies, given the high recurrence rate of GBM, typically within 6-9 months [4][6]. - The procedure demonstrated excellent feasibility, achieving over 95% coverage of the tumor volume with a novel delivery device that integrates seamlessly into standard neurosurgical workflows [7].